Global Custom Market Research Reports Provider Company

phone

Acceleron Pharma Inc (XLRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 11 Apr 2018
  • Number of Pages: 56
  • Category: Pharmaceuticals
  • Country: United States of America
Summary

Acceleron Pharma Inc (AcceleronPharma) is a clinical stage biopharmaceutical company that discovers, developsand commercializes therapeuticsto treat serious and rare diseases. The companys lead therapeutic candidate, luspatercept, is in phase 3 studyused for the treatment of the myelodysplastic syndromes, beta-thalassemia and myelofibrosis. It also offers pipeline products for the treatment of facioscapulohumeral muscular dystrophy, neuromuscular diseases, renal cell carcinoma and other indications. The company partners with various biopharmaceutical companies and research institutes to advance the development of its lead products. AcceleronPharma is headquartered in Cambridge, Massachusetts, the US.

Acceleron Pharma Inc (XLRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData

3
List of Tables 5
List of Figures 5
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acceleron Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Adimab Enters into Agreement with Acceleron Pharma 11
Licensing Agreements 12
Acceleron Pharma Enters into Licensing Agreement with Celgene 12
Acceleron Pharma Enters into Licensing Agreement with Beth Israel Deaconess Medical Center 14
Equity Offering 15
Acceleron Pharma Raises USD230 Million in Public Offering of Shares 15
Acceleron Pharma Raises USD150 Million in Public Offering of Shares 17
Acceleron Pharma Completes Public Offering Of Shares For US$138 Million 19
Acceleron Pharma Completes IPO For US$96.3 Million 21
Acceleron Pharma Completes Private Placement Of Shares For US$10 Million 23
Acceleron Pharma Inc - Key Competitors 25
Acceleron Pharma Inc - Key Employees 26
Acceleron Pharma Inc - Locations And Subsidiaries 27
Head Office 27
Recent Developments 28
Financial Announcements 28
Feb 27, 2018: Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results 28
Aug 03, 2017: Acceleron Pharma Reports Second Quarter 2017 Operational and Financial Results 30
May 08, 2017: Acceleron Pharma Reports First Quarter 2017 Operational and Financial Results 32
Mar 01, 2017: Acceleron Reports Fourth Quarter and Year Ended 2016 Operational and Financial Results 34
Corporate Communications 36
Nov 15, 2017: Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire 36
May 02, 2017: Acceleron Announces Management Change 37
Product News 38
11/01/2017: Acceleron to Present Sotatercept Clinical Data at 59th American Society of Hematology Annual Meeting and Exposition 38
Clinical Trials 39
Nov 14, 2017: Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions 39
Nov 01, 2017: Acceleron to Present Clinical Presentations on Investigational Drug Candidate Luspatercept at 59th American Society of Hematology Annual Meeting and Exposition 40
Sep 19, 2017: Acceleron Provides Clinical Update on Luspatercept at 2017 R&D Day 41
Sep 19, 2017: Acceleron Provides Clinical Update on Sotatercept at 2017 R&D Day 42
Sep 19, 2017: Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension 43
Sep 05, 2017: Acceleron Announces Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results in The Lancet Oncology 44
Jun 23, 2017: Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association 45
Jun 23, 2017: Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the European Hematology Association 47
Jun 01, 2017: Celgene and Acceleron Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia 49
May 18, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association 50
May 06, 2017: Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes 51
Apr 27, 2017: Acceleron Provides Clinical Development Updates on Luspatercept Program 53
Apr 06, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 14th International Symposium on Myelodysplastic Syndromes 54
Other Significant Developments 55
Jan 06, 2017: Acceleron Outlines Corporate Goals and Priorities for 2017 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List Of Tables

List of Tables
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acceleron Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acceleron Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adimab Enters into Agreement with Acceleron Pharma 11
Acceleron Pharma Enters into Licensing Agreement with Celgene 12
Acceleron Pharma Enters into Licensing Agreement with Beth Israel Deaconess Medical Center 14
Acceleron Pharma Raises USD230 Million in Public Offering of Shares 15
Acceleron Pharma Raises USD150 Million in Public Offering of Shares 17
Acceleron Pharma Completes Public Offering Of Shares For US$138 Million 19
Acceleron Pharma Completes IPO For US$96.3 Million 21
Acceleron Pharma Completes Private Placement Of Shares For US$10 Million 23
Acceleron Pharma Inc, Key Competitors 25
Acceleron Pharma Inc, Key Employees 26

List Of Figures

List of Figures
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Acceleron Pharma Inc (AcceleronPharma) is a clinical stage biopharmaceutical company that discovers, developsand commercializes therapeuticsto treat serious and rare diseases. The companys lead therapeutic candidate, luspatercept, is in phase 3

View Report

Acceleron Pharma Inc (AcceleronPharma) is a clinical stage biopharmaceutical company that discovers, developsand commercializes therapeuticsto treat serious and rare diseases. The companys lead therapeutic candidate, luspatercept, is in phase 3

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports